These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37189266)

  • 1. Adverse Drug Event Profile Associated with Anti-dementia Drugs: Analysis of a Spontaneous Reporting Database.
    Kose E; Yamamoto T; Tate N; Ando A; Enomoto H; Yasuno N
    Pharmazie; 2023 May; 78(5):42-46. PubMed ID: 37189266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
    Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease.
    Lampela P; Tolppanen AM; Tanskanen A; Tiihonen J; Lavikainen P; Hartikainen S; Taipale H
    Ann Med; 2017 May; 49(3):230-239. PubMed ID: 27786552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
    Inglis F
    Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of Pediatric Exposures to Antidementia Drugs Reported to a Poison Control System.
    Thornton SL; Pchelnikova JL; Cantrell FL
    J Pediatr; 2016 May; 172():147-50. PubMed ID: 26935787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada.
    Ali TB; Schleret TR; Reilly BM; Chen WY; Abagyan R
    PLoS One; 2015; 10(12):e0144337. PubMed ID: 26642212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
    Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
    Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study.
    Masurkar PP; Chatterjee S; Sherer JT; Chen H; Johnson ML; Aparasu RR
    Drugs Aging; 2022 Jun; 39(6):453-465. PubMed ID: 35666463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
    Noetzli M; Eap CB
    Clin Pharmacokinet; 2013 Apr; 52(4):225-41. PubMed ID: 23408070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylcholinesterase inhibitors and memantine for neuroenhancement in healthy individuals: a systematic review.
    Repantis D; Laisney O; Heuser I
    Pharmacol Res; 2010 Jun; 61(6):473-81. PubMed ID: 20193764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary).
    Tavassoli N; Sommet A; Lapeyre-Mestre M; Bagheri H; Montrastruc JL
    Drug Saf; 2007; 30(11):1063-71. PubMed ID: 17973542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of pneumonia in new users of cholinesterase inhibitors for dementia.
    Lai EC; Wong MB; Iwata I; Zhang Y; Hsieh CY; Kao Yang YH; Setoguchi S
    J Am Geriatr Soc; 2015 May; 63(5):869-76. PubMed ID: 25912671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
    Kavirajan H; Schneider LS
    Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug event profile associated with pregabalin among patients with and without cancer: analysis of a spontaneous reporting database.
    Kose E
    J Clin Pharm Ther; 2018 Aug; 43(4):543-549. PubMed ID: 29574893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs for cognitive loss and dementia.
    Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.